Equities analysts expect that ICU Medical (NASDAQ:ICUI) will report earnings of $1.81 per share for the current quarter, according to Zacks. Two analysts have made estimates for ICU Medical’s earnings, with the lowest EPS estimate coming in at $1.77 and the highest estimate coming in at $1.85. ICU Medical posted earnings of $1.68 per share during the same quarter last year, which would suggest a positive year over year growth rate of 7.7%. The business is scheduled to report its next earnings results after the market closes on Wednesday, May 9th.
On average, analysts expect that ICU Medical will report full year earnings of $7.00 per share for the current year, with EPS estimates ranging from $6.90 to $7.16. For the next fiscal year, analysts anticipate that the firm will report earnings of $8.84 per share, with EPS estimates ranging from $8.35 to $9.36. Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research firms that follow ICU Medical.
ICU Medical (NASDAQ:ICUI) last issued its earnings results on Thursday, March 1st. The medical instruments supplier reported $2.98 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.04 by $1.94. The firm had revenue of $370.12 million during the quarter, compared to the consensus estimate of $332.91 million. ICU Medical had a return on equity of 8.42% and a net margin of 5.31%. The business’s quarterly revenue was up 286.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.20 earnings per share.
ICUI has been the subject of several research analyst reports. Zacks Investment Research downgraded ICU Medical from a “buy” rating to a “hold” rating in a research note on Wednesday, January 10th. BidaskClub raised ICU Medical from a “hold” rating to a “buy” rating in a research note on Wednesday, March 7th. Two investment analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $266.00.
In other news, Director Robert S. Swinney sold 724 shares of the company’s stock in a transaction that occurred on Friday, January 19th. The stock was sold at an average price of $235.00, for a total value of $170,140.00. Following the completion of the transaction, the director now owns 14,830 shares of the company’s stock, valued at $3,485,050. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director George A. Lopez sold 7,894 shares of the company’s stock in a transaction that occurred on Monday, April 2nd. The shares were sold at an average price of $246.71, for a total value of $1,947,528.74. Following the completion of the transaction, the director now directly owns 494,025 shares of the company’s stock, valued at approximately $121,880,907.75. The disclosure for this sale can be found here. In the last three months, insiders have sold 56,176 shares of company stock valued at $13,945,286. Insiders own 13.60% of the company’s stock.
Several institutional investors have recently added to or reduced their stakes in ICUI. Point72 Asset Management L.P. acquired a new position in shares of ICU Medical in the third quarter valued at approximately $22,246,000. BlackRock Inc. increased its stake in shares of ICU Medical by 3.4% in the fourth quarter. BlackRock Inc. now owns 1,879,874 shares of the medical instruments supplier’s stock valued at $406,052,000 after buying an additional 62,605 shares during the period. Castleark Management LLC increased its stake in shares of ICU Medical by 3,016.5% in the fourth quarter. Castleark Management LLC now owns 51,110 shares of the medical instruments supplier’s stock valued at $11,040,000 after buying an additional 49,470 shares during the period. Gotham Asset Management LLC acquired a new position in shares of ICU Medical in the fourth quarter valued at approximately $9,242,000. Finally, Raymond James Financial Services Advisors Inc. increased its stake in shares of ICU Medical by 312.0% in the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 49,448 shares of the medical instruments supplier’s stock valued at $10,681,000 after buying an additional 37,445 shares during the period. 76.92% of the stock is owned by institutional investors.
Shares of NASDAQ ICUI opened at $255.85 on Wednesday. The stock has a market cap of $5,205.60, a price-to-earnings ratio of 46.35, a price-to-earnings-growth ratio of 2.58 and a beta of 0.36. ICU Medical has a 12 month low of $144.25 and a 12 month high of $265.27.
COPYRIGHT VIOLATION NOTICE: This article was originally posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this article can be viewed at https://ledgergazette.com/2018/04/14/brokerages-expect-icu-medical-icui-will-post-earnings-of-1-81-per-share.html.
About ICU Medical
ICU Medical, Inc develops, manufactures, and sells medical devices used in infusion therapy, critical care, and oncology applications worldwide. It offers infusion therapy products comprising a tube running from a bottle or plastic bag containing a solution to a catheter inserted in a patient's vein for use in hospitals and ambulatory clinics.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ICU Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICU Medical and related companies with MarketBeat.com's FREE daily email newsletter.